{"url_path":"/sec/zvsa/8-k/2026-07-16/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1859007/0001493152-26-033565-index.html","accession_number":"0001493152-26-033565","cik":"0001859007","ticker":"ZVSA","issuer_name":"ZyVersa Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1859007/0001493152-26-033565-index.html","primary_entity_key":"0001859007","primary_entity_name":"ZyVersa Therapeutics, Inc."},"word_count":73,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events.**\n\n \n\nEffective\nJuly 16, 2026, ZyVersa Therapeutics, Inc. ceased trading on the OTCQB® Venture Market and commenced trading on the OTC Pink Limited\nMarket.\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDate:\nJuly 16, 2026\nZYVERSA\nTHERAPEUTICS, INC.\n\n \n \n\n \n*/s/\nStephen Glover*\n\n \nStephen\nGlover\n\n \nChief\nExecutive Officer"}